Just 38 million shares outstanding and enough cash for a year.
Interesting. Was the CRO’s motive ever discovered in this case?
>>This is a final and binding decision and to CEL-SCI’s knowledge, marks the first ever decision in favor of a biomedical company against a CRO for breach of contract"